

List of Supplementary Files

Table S1. PRISMA checklist

Table S2. Search strategy for peer-reviewed databases

Table S3. The characteristics of included studies comparing severe and non-severe COVID-19 patients

Table S4. The characteristics of included studies comparing survivors and non-survivors of COVID-19

Table S5. Risk of bias assessment of all included studies using the Newcastle-Ottawa Scale (NOS)

Figure S1. Meta-analysis restricted to only peer-reviewed studies comparing the NLR value on admission in severe vs. non-severe COVID-19 patients

Figure S2. Meta-analysis restricted to studies with low risk of bias score comparing the NLR value on admission in severe vs. non-severe COVID-19 patients

Figure S3. Bubble plot for meta-regression in studies with severity outcome

Figure S4. Meta-analysis restricted to only peer-reviewed studies comparing the NLR value on admission in survivors vs. non-survivors of COVID-19

Figure S5. Meta-analysis restricted to studies with low risk of bias score comparing the NLR value on admission in survivors vs. non-survivors of COVID-19

Figure S6. Bubble plot for meta-regression in studies with mortality outcome

Table S1. PRISMA checklist.

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	3
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	4
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	4
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	4
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	4, Supplementary file
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	5, 6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	5
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	5, 6
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	6

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	7, 24
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	7, 20-22, Supplementary files
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	7, 20-22, Supplementary files
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	7-9, 20-23,
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	8-10, 23, 25-27, Supplementary files
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	8-9, 25, 27
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	8, 9, 26, Supplementary files
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	11-13,
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	13
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	14
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	15

Table S2. Search strategy for peer-reviewed databases. Search results were done on 23 July 2020.

Database	Search Terms	Hits
Ovid MEDLINE	1. COVID-19 2. COVID19 3. COVID 4. "Coronavirus disease 2019" 5. 2019-nCoV 6. SARS-CoV-2 7. 1 OR 2 OR 3 OR 4 OR 5 OR 6 8. neutrophil-to-lymphocyte 9. NLR 10. 8 OR 9 11. Sever* 12. "Intensive care unit" 13. ICU 14. Mortality 15. Death 16. Non-survivor 17. 11 OR 12 OR 13 OR 14 OR 15 OR 16 18. 7 AND 10 AND 17	94
Ovid EMBASE	1. COVID-19 2. COVID19 3. COVID 4. "Coronavirus disease 2019" 5. 2019-nCoV 6. SARS-CoV-2 7. 1 OR 2 OR 3 OR 4 OR 5 OR 6 8. neutrophil-to-lymphocyte 9. NLR 10. 8 OR 9 11. Sever* 12. "Intensive care unit" 13. ICU 14. Mortality 15. Death 16. Non-survivor 17. 11 OR 12 OR 13 OR 14 OR 15 OR 16 18. 7 AND 10 AND 17	58
SCOPUS	(TITLE-ABS-KEY(COVID-19) OR TITLE-ABS-KEY(COVID19) OR TITLE-ABS-KEY(COVID) OR TITLE-ABS-KEY("coronavirus disease 2019") OR TITLE-ABS-KEY(2019-ncov) OR TITLE-ABS-KEY(sars-cov-2)) AND (TITLE-ABS-KEY(neutrophil-to-lymphocyte) OR TITLE-ABS-KEY(NLR)) AND (TITLE-ABS-KEY(sever*) OR TITLE-ABS-KEY("intensive care unit") OR TITLE-ABS-KEY(ICU) OR TITLE-ABS-KEY(mortality) OR TITLE-ABS-KEY(death) OR TITLE-ABS-KEY(non-survivor))	49
The Cochrane Library	("Covid-19" OR "COVID19" OR "COVID" OR "coronavirus disease 2019" OR "2019-nCoV" OR "SARS-CoV-2") in Title Abstract Keyword AND (neutrophil-to-lymphocyte OR NLR) in Title Abstract Keyword AND (sever* OR "intensive care unit" OR ICU OR mortality OR death OR non-survivor)	2
Total		203

Table S3. The characteristics of included studies comparing severe and non-severe COVID-19 patients.

Author	Groups	Sample (N)	M/F (male %)	p	Age (years) Mean ± SD / Median (IQR)	p	DM N (%)	p	HT N (%)	p	CVD N (%)	p	NLR Value Mean ± SD / Median (IQR)	p
Qin C et al	Severe	286	155/131 (54)	0.242	61 (51-69)	<0.001*	53 (19)	0.152	105 (37)	<0.001*	24 (8)	0.004*	5.5 (3.3-10.0)	<0.001*
	Non-severe	166	80/86 (48)		53 (41-62)		22 (13)		30 (18)		3 (2)		3.2 (1.8-4.9)	
Zhang Y et al	Severe	31	20/11 (65)	0.004*	65 ± 13	<0.001*	NR	NR	NR	NR	NR	NR	7.58 ± 7.04	<0.001*
	Mild	84	29/55 (35)		44 ± 15		NR		NR		NR		2.28 ± 1.29	
Yang AP et al	Severe	24	18/6 (75)	0.135	58 ± 12	<0.05*	13 (54)	<0.01*	16 (67)	<0.01*	9 (38)	<0.01*	20.7 ± 24.1	<0.01*
	Non-severe	69	38/31 (55)		42 ± 19		8 (12)		7 (10)		4 (6)		4.8 ± 3.5	
Gong J et al	Severe	28	16/12 (57)	0.3	64 (55-72)	<0.01*	NR	NR	NR	NR	NR	NR	3.7 (2.0-6.7)	<0.01*
	Non-severe	161	72/89 (45)		45 (33-62)		NR		NR		NR		1.9 (1.4-2.9)	
Zhu Z et al	Severe	16	9/7 (56)	0.457	58 ± 12	0.03*	0 (0)	0.451	8 (50)	0.025*	2 (13)	0.348	4.24 (3.00-10.87)	0.015*
	Non-severe	111	73/38 (66)		50 ± 16		10 (9)		23 (21)		4 (4)		2.75 (1.90-3.95)	
Sun S et al	Severe	27	18/9 (67)	0.076	62 (53-71)	<0.001*	NR	NR	NR	NR	NR	NR	8.71 (3.77-14.4)	<0.001*
	Common	89	42/47 (47)		47 (37-55)		NR		NR		NR		2.41 (1.73-3.47)	
Liu F et al	Severe	19	15/4 (79)	0.006*	63 (40-66)	0.086	3 (16)	0.152	6 (32)	0.217	1 (5)	0.540	3.4 (2.8-5.8)	0.010*
	Non-severe	115	48/67 (42)		50 (36-64)		7 (6)		21 (18)		4 (4)		2.7 (1.8-3.7)	
Fu J et al	Severe	16	10/6 (63)	0.818	52 ± 13	0.095	4 (5)	NR	7 (9)	NR	NR	NR	6.29 ± 3.72	0.001*
	Mild/moderate	59	35/24 (59)		45 ± 14		NR		NR		NR		2.33 ± 1.22	
Ding X et al	Severe	15	9/6 (60)	0.216	67 (55-76)	<0.001*	5 (7)	NR	9 (13)	NR	6 (8)	NR	3.6 (2.4-9.6)	0.002*
	Non-severe	57	24/33 (42)		46 (35-60)		NR		NR		NR		1.9 (1.3-2.9)	
Chen R et al	Critical	48	38/10 (79)	NR	61 ± 14	<0.001*	5 (10)	NR	23 (48)	NR	7 (15)	NR	16.06 (11.26-26.35)	<0.001*
	Severe	155	93/62 (60)		61 ± 14		23 (15)		52 (34)		14 (9)		8.96 (4.62-17.04)	
	Mild/moderate	345	182/163 (53)		67 ± 12		33 (10)		73 (21)		14 (4)		3.37 (2.05-6.65)	
Shang W et al	Severe	139	82/57 (59)	0.008*	64 (54-73)	<0.001*	20 (14)	0.946	45 (32)	0.382	25 (18)	<0.001*	4.75 (2.51-9.42)	<0.001*
	Non-severe	304	138/166 (45)		58 (47-67)		43 (14)		86 (28)		19 (6)		2.38 (1.57-3.72)	
Xie G et al	Severe	12	10/2 (83)	0.003*	52 (35-66)	0.092	2 (17)	0.068	4 (33)	0.042*	2 (17)	0.032*	3.0 (1.56-6.55)	0.026*
	Non-severe	85	43/42 (51)		45 (32-60)		3 (4)		16 (19)		5 (6)		2.74 (2.03-3.96)	
Xie L et al	Severe	51	29/22 (57)	0.039*	NR	NR	8 (16)	0.0466*	12 (24)	0.3790	6 (12)	0.0130*	7.90 ± 10.20	<0.0001*
	Non-severe	322	168/154 (52)		NR		21 (7)		59 (18)		12 (4)		2.93 ± 1.80	
Zhou Y et al	Moderate	140	55/85 (39)	NR	56 ± 14	<0.001*	NR	NR	NR	NR	NR	NR	3.1 ± 2.41	NR
	Severe	123	58/65 (47)		64 ± 14		NR		NR		NR		11.66 ± 27.66	
	Critically severe	41	25/16 (61)		65 ± 13		NR		NR		NR		NR	
Wu S et al	Severe or critical	67	45/22 (67)	NR	66 (54-73)	<0.001*	8 (12)	NR	22 (33)	NR	6 (9)	NR	5.8 (3.3-13.0)	NR
	Moderate	203	86/117 (42)		61 (50-68)		27 (13)		59 (29)		5 (3)		2.2 (1.5-3.4)	
Kong M et al	Severe	87	45/42 (52)	0.592	68 ± 12	0.005*	18 (21)	0.004*	47 (54)	<0.001*	11 (13)	0.195	6.6 (2.1-11.1)	<0.001*
	Mild	123	59/64 (48)		53 ± 16		9 (7)		32 (26)		9 (7)		3.3 (1.0-3.4)	
Wang F et al	Severe	70	45/25 (64)	0.002*	60 (49-64)	<0.001*	NR	NR	NR	NR	NR	NR	2.72 (1.87-4.37)	<0.001*
	Non-severe	253	109/144 (43)		41 (32-56)		NR		NR		NR		1.72 (1.19-2.53)	
Liao D et al	Critical	86	61/25 (71)	0.0011*	68 (61-78)	<0.0001*	17 (20)	0.017*	28 (33)	0.21	8 (9)	0.085	16.02 (6.49-24.79)	<0.0001*
	Severe	145	76/69 (52)		67 (58-76)		30 (21)		49 (34)		8 (6)		4.71 (2.62-7.78)	
	Moderate	149	69/80 (46)		56 (42-68)		14 (9)		37 (25)		4 (3)		2.67 (1.69-4.08)	

Ok F et al	Severe	54	24/30 (44)	0.976	68 ± 15	<0.001*	3 (13)	0.378	10 (44)	0.001*	6 (26)	0.004*	6.1 (5.1)	<0.001*
	Non-severe	85	38/47 (45)		47 ± 16		4 (7)		6 (10)		2 (3)		2.46 (2.3)	
Guner R et al	SARI/Critical	50	33/17 (66)	0.285	62 ± 12	<0.001*	10 (20)	0.127	16 (32)	0.104	20 (40)	0.006*	5.6 (1.5-38)##	<0.001*
	Mild/pneumonia	172	99/73 (58)		48 ± 16		20 (12)		36 (21)		36 (21)		2.5 (0.4-28)##	
Song CY et al	Severe	42	30/12 (71)	0.083	56 (48-64)	0.039*	4 (10)	0.637	22 (52)	<0.001*	4 (10)	0.292	8.2 (3.9-19.2)	0.001*
	Non-severe	31	16/15 (52)		48 (37-59)		2 (7)		4 (13)		1 (3)		3.0 (1.9-5.5)	
Liu J et al	Severe	79	46/33 (58)	0.849	65 (54-71)	0.008*	13 (17)	0.082	37 (47)	0.086	2 (3)	0.540	8.83 (4.20-15.53)	<0.001*
	Common	43	26/17 (61)		55 (38-66)		2 (5)		13 (30)		0 (0)		3.11 (1.96-5.00)	
Ma Y et al	Severe	63	29/34 (46)	0.113	53 ± 13	<0.0001*	6 (10)	NR	15 (24)	NR	NR	NR	9.38 ± 10.52	<0.0001*
	Ordinary (Moderate)	486	262/224 (54)		45 ± 15		23 (5)		75 (15)		NR		3.58 ± 3.07	
	Mild	86	37/49 (43)		39 ± 18		6 (7)		15 (17)		NR		2.73 ± 2.28	
Chen C et al	Critical	23	15/8 (65)	0.152	68 (63-79)	0.025*	9 (39)	0.575	19 (83)	0.102	7 (30)	0.387	7.08 (3.48-12.89)	0.010*
	Mild	109	61/48 (56)		62 (53-70)		36 (27)		71 (65)		24 (22)		4.10 (2.19-7.51)	
Wang J et al	Severe	8	27/28 (49)	NR	45 (25-61)	NR	5 (9)	NR	13 (24)	NR	1 (2)	NR	2.4 (1.4-16.2)	NR
	Moderate	25			2.3 (1.7-2.9)									
	Mild	22			1.8 (0.9-2.8)									

CVD = Cardiovascular disease; DM = Diabetes mellitus; HT = Hypertension; IQR = Interquartile range; NLR = Neutrophil-to-lymphocyte ratio; NR = Not reported; p = p-value; SD = Standard deviation; # = Minimum to maximum; * = Statistically significant

Table S4. The characteristics of included studies comparing survivors and non-survivors of COVID-19.

Author	Groups	Sample (N)	M/F (male%)	p	Age (years) Mean ± SD / Median (IQR)	p	DM N (%)	p	HT N (%)	p	CVD N (%)	p	NLR value Mean ± SD / Median (IQR)	p
Liu Y et al	NLR Tertile 1 (0.54-2.21)	82	24/58 (29)	<0.001*	48 ± 16	<0.001*	5 (6)	0.131	11 (13)	0.005*	5 (6)	0.100	NR	NR
	NLR Tertile 2 (2.21-4.82)	81	40/41 (49)		53 ± 17		6 (7)		14 (17)		3 (4)		NR	
	NLR Tertile 3 (4.85-88.09)	82	50/32 (61)		61 ± 15		12 (15)		27 (33)		10 (12)		NR	
Chen R et al	Survivor	445	244/201 (55)	<0.05*	54 ± 14	<0.01*	41 (9)	<0.01*	103 (23)	<0.01*	24 (5)	>0.05	3.71 (2.27-7.54)	<0.001*
	Non-survivor	103	69/34 (67)		67 ± 12		20 (19)		45 (44)		11 (11)		13.45 (9.33-23.60)	
Huang J et al	Survivor	283	149/134 (53)	0.318	53 ± 17	<0.001*	31 (11)	0.103	63 (22)	<0.001*	14 (5)	0.011*	3.3 ± 4.3	0.013*
	Non-survivor	16	11/5 (69)		69 ± 10		4 (25)		11 (69)		4 (25)		13.3 ± 14.3	
Zhang N et al	Survivor	50	36/14 (72)	NR	63 ± 11	0.044*	5 (10)	0.025*	18 (36)	0.811	11 (22)	0.587	8.4 ± 7.5	0.030*
	Non-survivor	10	7/3 (70)		71 ± 9		4 (40)		4 (40)		3 (30)		18.7 ± 16.6	
Li L et al	Survivor	68	26/42 (38)	0.098	44 ± 13	<0.01*	6 (9)	0.158	0 (0)	NR	0 (0)	NR	2.3 (1.6-3.8)	<0.0001*
	Non-survivor	25	15/10 (60)		69 ± 11		5 (20)		5 (20)		4 (16)		0.2 (0.1-0.5)	
Luo X et al	Survivor	214	99/115 (46)	0.025*	51 (37-63)	<0.001*	27 (13)	0.056	37 (17)	<0.001*	13 (6)	0.010*	2.96 (2.13-4.61)	<0.001*
	Non-survivor	84	51/33 (61)		71 (64-80)		18 (21)		49 (58)		13 (16)		8.17 (6.15-10.90)	
Yan X et al	Survivor	964	466/498 (48)	0.018*	62 (50-70)	0.007*	97 (11)	0.003*	215 (22)	<0.001*	65 (7)	<0.001*	4.11(2.44-8.12)	<0.001*
	Non-survivor	40	27/13 (68)		68 (58-79)		10 (25)		20 (50)		10 (25)		49.06(25.71-69.70)	
Chen L et al	Survivor	1651	781/870 (47)	<0.001*	57 (43-66)	<0.001*	203 (12)	<0.001*	475 (29)	<0.001*	205 (12)\$	<0.001*	3 (2-4)	<0.001*
	Non-survivor	208	153/55 (74)		70 (63-78)		59 (28)		104 (50)		62 (30)\$		11 (6-20)	
Tatum D et al	NLR ≤ 4.94	62	27/35 (43)	0.605	56 ± 15	0.007*	NR	NR	NR	NR	NR	NR	NR	NR
	NLR > 4.94	57	27/30 (47)		62 ± 14		NR		NR		NR		NR	
Ullah W et al	NLR < 10	141	66/75 (47)	0.167	64	0.71	49 (35)	0.716	93 (66)	0.237	27 (19)	0.16	NR	NR
	NLR > 11	26	16/10 (62)		62		10 (39)		14 (54)		2 (8)		NR	
Ye W et al	Survivor	297	137/160 (46)	0.002*	60 (50-67)	<0.001*	41 (14)	0.004*	73 (25)	<0.001*	5 (2)	<0.001*	2.88 (1.79-6.74)	<0.001*
	Non-survivor	52	36/16 (69)		69 (63-76)		16 (31)		30 (58)		11 (21)		14.96 (8.52-26.58)	
Yang Q et al	Survivor	176	82/94 (47)	0.077	50 ± 15	<0.001*	28 (16)	0.008*	47 (27)	<0.001*	6 (3)	0.010*	2.98 (1.70-5.51)	<0.001*
	Non-survivor	50	31/19 (62)		68 ± 16		17 (34)		37 (74)		7 (14)		6.18 (3.58-12.78)	
Zhang S et al	Survivor	420	213/207 (51)	NR	59 (48-67)	NR	60 (14)	NR	107 (26)	NR	53 (13)	NR	3.91 (2.07-6.79)	<0.001*
	Non-survivor	96	72/24 (75)		67 (61-74)		16 (17)		31 (32)		14 (15)		10.99 (7.68-20.97)	
Cheng B et al	Survivor	67	22/45 (33)	0.002*	71 ± 7	0.048*	11 (16)	0.055	39 (58)	0.321	11 (16)	0.334	4.1 ± 2.9	<0.001*
	Non-survivor	51	31/20 (61)		73 ± 7		16 (31)		25 (49)		12 (24)		13.3 ± 14.9	
Chen C et al	Survivor	119	67/52 (56)	0.371	NR	NR	42 (35)	0.378	80 (68)	0.476	24 (20)	0.007*	4.19 (2.30-7.39)	0.007*
	Non-survivor	13	9/4 (69)		NR		3 (23)		10 (77)		7 (54)		12.21 (3.66-14.98)	

CVD = Cardiovascular disease; DM = Diabetes mellitus; HT = Hypertension; IQR = Interquartile range; NLR = Neutrophil-to-lymphocyte ratio; NR = Not reported; p = p-value; SD = Standard deviation; \$ = Included cerebrovascular disease; * = Statistically significant

Table S5. Risk of bias assessment of all included studies using the Newcastle-Ottawa Scale (NOS).

No	Author	Date of Publication	Publication Type	Study Location	Study Period	Study Design	Selection	Comparability	Outcome/Exposure
1	Qin C et al	12/03/2020	Peer-reviewed	Tongji Hospital, Wuhan, China	10 Jan 20 to 12 Feb 20	Retrospective Observational	**	-	***
2	Zhang Y et al	30/03/2020	Peer-reviewed	Zhongnan Hospital, Wuhan, China	18 Jan 20 to 22 Feb 20	Retrospective Observational	**	**	***
3	Yang AP et al	13/04/2020	Peer-reviewed	China	NR	Retrospective Observational	**	**	***
4	Gong J et al	16/04/2020	Peer-reviewed	Guangzhou Eighth Peoples Hospital, Zhongnan Hospital, Third Affiliated Hospital, China	20 Jan 20 to 02 Mar 20	Retrospective Observational	***	*	***
5	Zhu Z et al	17/04/2020	Peer-reviewed	Hwa Mei Hospital, Zhejiang, China	23 Jan 20 to 20 Feb 20	Retrospective Observational	**	**	***
6	Liu Y et al	20/04/2020	Peer-reviewed	Zhongnan Hospital, Wuhan, China	1 Jan 20 to 29 Feb 20	Retrospective Observational	***	**	***
7	Sun S et al	24/04/2020	Peer-reviewed	Wenzhou, China	19 Jan 20 to 20 Feb 20	Retrospective Observational	**	-	***
8	Liu F et al	27/04/2020	Peer-reviewed	Shanghai Public Health Clinical Center, Shanghai, China	20 Jan 20 to 3 Feb 20	Retrospective Observational	***	**	***
9	Fu J et al	06/05/2020	Peer-reviewed	Affiliated Infectious Diseases Hospital, Suzhou, China	20 Jan 20 to 10 Mar 20	Retrospective Observational	**	*	***
10	Ding X et al	10/05/2020	Peer-reviewed	Beijing YouAn Hospital, Beijing, China	21 Jan 20 to 20 Mar 20	Retrospective Observational	**	**	***
11	Chen R et al	11/05/2020	Peer-reviewed	575 hospitals, China	Up to 22 Mar 20	Retrospective Observational	****	**	***
12	Huang J et al	11/05/2020	Peer-reviewed	Third People's Hospital of Yichang, Hubei, China	25 Jan 20 to 24 Mar 20	Retrospective Observational	***	**	***
13	Zhang N et al	14/05/2020	Peer-reviewed	WuGang General Hospital, Wuhan; and First Affiliated Hospital of Hunan University of Medicine, Hunan, China	9 Jan 20 to 19 Feb 20	Retrospective Observational	***	-	***
14	Li L et al	15/05/2020	Peer-reviewed	Union Hospital, Wuhan, China	10 Jan 20 to 22 Feb 20	Retrospective Observational	***	*	***
15	Shang W et al	15/05/2020	Peer-reviewed	Wuhan Forth Hospital, Wuhan, China	16 Jan 20 to 28 Feb 20	Retrospective Observational	**	**	***
16	Luo X et al	23/05/2020	Peer-reviewed	Eastern Campus of Renmin Hospital, Wuhan, China	30 Jan 20 to 20 Feb 20	Retrospective Observational	***	**	***
17	Yan X et al	26/05/2020	Peer-reviewed	Wuhan Third Hospital & Tongren Hospital, Wuhan, China	11 Jan 20 to 3 Mar 20	Retrospective Observational	***	**	***

18	Xie G et al	27/05/2020	Peer-reviewed	Shanghai Public Health Clinical Center, Shanghai, China	20 Jan 20 to 20 Feb 20	Retrospective Observational	**	-	***
19	Xie L et al	15/06/2020	Peer-reviewed	Shanghai Public Health Clinical Center and Affiliated Hospital of Putian University, Shanghai, China	20 Jan 20 to 29 Feb 20	Retrospective Observational	**	-	***
20	Chen L et al	16/06/2020	Peer-reviewed	Union Hospital (Main, Union West and Union Tumor Hospital), Wuhan Central Hospital, General Hospital of Central Theater Command, PLA Wuhan Third Hospital, Wuhan Jin-Yin-Tan Hospital, Wuhan, China	20 Jan 20 to 4 Apr 20	Retrospective Observational	****	**	***
21	Zhou Y et al	16/06/2020	Peer-reviewed	Wuhan Red Cross Hospital, Wuhan, China	1 Feb 20 to 15 Mar 20	Retrospective Observational	**	-	***
22	Wu S et al	18/06/2020	Peer-reviewed	Wuhan Fourth Hospital, Wuhan, China	27 Jan 20 to 26 Feb 20	Retrospective Observational	**	**	***
23	Tatum D et al	19/06/2020	Peer-reviewed	Two hospital, Southern Louisiana, USA	NR	Prospective Observational	***	-	***
24	Ullah W et al	25/06/2020	Peer-reviewed	Abington Hospital-Jefferson Health, Philadelphia, USA	1 Mar 20 to 10 May 20	Retrospective Observational	***	**	***
25	Kong M et al	30/06/2020	Peer-reviewed	Central Hospital of Wuhan, Wuhan, China	27 Jan 20 to 9 Mar 20	Retrospective Observational	**	**	***
26	Wang F et al	03/07/2020	Peer-reviewed	Third People's Hospital, Shenzhen, China	10 Jan 20 to 10 Feb 20	Retrospective Observational	***	**	***
27	Ye W et al	03/07/2020	Peer-reviewed	Wuhan Pulmonary Hospital Wuhan, China	1 Jan 20 to 16 Mar 20	Retrospective Observational	***	**	***
28	Yang Q et al	06/07/2020	Peer-reviewed	Central Hospital of Wuhan, China	1 Jan 20 to 29 Feb 20	Retrospective Observational	***	**	***
29	Liao D et al	10/07/2020	Peer-reviewed	Wuhan Union Hospital (Main campus, West Campus, and Cancer Centre)	23 Jan 20 to 23 Feb 20	Retrospective Observational	**	**	***
30	Ok F et al	10/07/2020	Peer-reviewed	Siirt State Hospital, Siirt, Turkey	Apr 20 to May 20	Retrospective Observational	**	**	***
31	Guner R et al	15/07/2020	Peer-reviewed	Ankara City Hospital, Ankara, Turkey	10 Mar 20 to 10 Apr 20	Retrospective Observational	**	*	***
32	Zhang S et al	16/07/2020	Peer-reviewed	Wuhan Union Hospital West Area, Wuhan, China	12 Jan 20 to 18 May 20	Retrospective Observational	***	*	***
33	Song CY et al	05/03/2020	Preprint	First Affiliated Hospital, Hangzhou, China	20 Jan 20 to 19 Feb 20	Retrospective Observational	**	**	**

34	Liu J et al	24/03/2020	Preprint	Jinyintan Hospital, Wuhan, China	13 Jan 20 to 25 Feb 20	Retrospective Observational	**	**	***
35	Cheng B et al	14/04/2020	Preprint	Union Dongxihu Hospital, Wuhan, China	12 Jan 20 to 26 Feb 20	Retrospective Observational	***	**	***
36	Ma Y et al	14/04/2020	Preprint	43 hospitals in China	28 Jan 20 to 25 Feb 20	Retrospective Observational	**	**	**
37	Chen C et al	07/05/2020	Preprint	Hubei Third People's Hospital, Hubei, China	19 Jan 20 to 7 Mar 20	Retrospective Observational	***	**	***
38	Wang J et al	26/05/2020	Preprint	Fifth People's Hospital, Wuxi, China	23 Jan 20 to 15 Mar 20	Retrospective Observational	**	-	***

Figure S1. Meta-analysis restricted to only peer-reviewed studies comparing the NLR value on admission in severe vs. non-severe COVID-19 patients.




Figure S2. Meta-analysis restricted to studies with low risk of bias score comparing the NLR value on admission in severe vs. non-severe COVID-19 patients.




Figure S3. Bubble plot for meta-regression in studies with severity outcome. The association between NLR values on admission and COVID-19 severity was not affected by gender (A), diabetes mellitus (B), hypertension (C), and cardiovascular diseases (D).




Figure S4. Meta-analysis restricted to only peer-reviewed studies comparing the NLR value on admission in survivors vs. non-survivors of COVID-19.




Figure S5. Meta-analysis restricted to studies with low risk of bias score comparing the NLR value on admission in survivors vs. non-survivors of COVID-19.




Figure S6. Bubble plot for meta-regression in studies with mortality outcome. The association between NLR values on admission and COVID-19 mortality was not affected by gender (A), diabetes mellitus (B), hypertension (C), and cardiovascular diseases (D).

